[]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody being evaluated for treating acute respiratory distress syndrome.

                          Product Name : Ifx-1

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 15, 2024

                          Lead Product(s) : Ifx-1

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank